Neuroone Medical Technologies Corp

NASDAQ:NMTCUnited States

May 14, 2024

Show headlines and story abstract

• NeuroOne(R) Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update, from 4:00PM ET on Tuesday May 14, 2024 by GlobeNewswire

  4:00PM ET on Tuesday May 14, 2024 by GlobeNewswire
  Companies Mentioned: NMTC

• NeuroOne(R) Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update, from 4:00PM ET on Tuesday May 14, 2024 by Dow Jones

  4:00PM ET on Tuesday May 14, 2024 by Dow Jones
  Companies Mentioned: NMTC
  
  about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward--looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward--looking statements for any reason, even if new information becomes available in the future.
  

• *DJ NeuroOne Medical Tech 2Q Rev $1.38M >NMTC, from 4:00PM ET on Tuesday May 14, 2024 by Dow Jones

  4:00PM ET on Tuesday May 14, 2024 by Dow Jones
  Companies Mentioned: NMTC

• NeuroOne(R) Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update, from 4:00PM ET on Tuesday May 14, 2024 by Dow Jones

  4:00PM ET on Tuesday May 14, 2024 by Dow Jones
  Companies Mentioned: NMTC
  
  Biomet may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward--looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward--looking statements for any reason, even if new information becomes available in the future.